US20090071905A1 - Methods of Making and Using Filtering Unit for a Virucide Substance - Google Patents
Methods of Making and Using Filtering Unit for a Virucide Substance Download PDFInfo
- Publication number
- US20090071905A1 US20090071905A1 US12/053,929 US5392908A US2009071905A1 US 20090071905 A1 US20090071905 A1 US 20090071905A1 US 5392908 A US5392908 A US 5392908A US 2009071905 A1 US2009071905 A1 US 2009071905A1
- Authority
- US
- United States
- Prior art keywords
- polymer
- hydrophilic
- filter medium
- copolymer
- biological fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
- B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0017—Filtration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
- A61M1/3686—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents by removing photoactive agents after irradiation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Definitions
- the virucidal substance has previously been added to a biological fluid, in particular blood plasma, intended to be transfused into a patient.
- the aim of this addition is to subject the biological fluid to a viral inactivation treatment prior to its transfusion into the patient, so as to inactivate any viruses infecting the biological fluid.
- a conventional technique for viral inactivation of plasma uses a colouring substance as a virucidal substance, for example methylene blue or one of its derivatives.
- the invention therefore aims to propose a filtration unit which makes it possible to remove substantially all the virucidal substance present in the biological fluid while leaving the composition of the biological fluid substantially unchanged during the filtration.
- the object of the invention is a filtration unit intended to remove a virucidal substance present in a biological fluid, comprising an outer casing provided with at least one input aperture and at least one output aperture, the casing containing a filter medium which delimits two compartments, respectively input and output, of the filtration unit, in which the filter medium is produced from at least one hydrophilic material in the form of a porous non-woven material and/or a porous membrane capable of absorbing and/or adsorbing the virucidal substance.
- the mean porosity of the filter medium is defined so that the contact area between the biological fluid and the filter medium is sufficient to remove substantially all the virucidal substance while leaving the composition of the biological fluid substantially unchanged during its passage through the filter medium, namely being between 1 ⁇ m and 15 ⁇ m.
- the mean diameter of the fibres of the porous non-woven material is between 0.5 ⁇ m and 5 ⁇ m.
- the input compartment and/or the output compartment communicate with the outside of the filtration unit by means of an input, respectively output, tube.
- the filter medium has for example a thickness between 1 and 10 millimetres.
- FIG. 3 depicts, in top view and transverse section, the embodiment of FIG. 1 , showing in particular the assembly of the frame containing the filter medium in the outer casing.
- FIG. 4 depicts, in front view and partial longitudinal section, the filtration unit of FIG. 3 in which the spacing rods appear.
- the biological fluid Prior to its passage into the filtration unit 1 , the biological fluid has undergone a viral inactivation treatment by means of the virucidal substance which was added to the biological fluid.
- the filtration unit 1 is disposed on the flow path of the biological fluid so that the biological fluid with the virucidal substance added enters the filtration unit 1 by the input aperture 3 and the biological fluid free from the virucidal substance is delivered by means of the output aperture 4 .
- flexible rods are used, in order not to interfere with the possibilities of folding the filtration unit 1 .
- the filter medium 5 is produced from at least one hydrophilic material in the form of a porous membrane.
- the filter medium 5 is produced from a hydrophilic material in the form of at least one porous membrane which is inserted between a number of layers of hydrophilic material in the form of a non-woven material.
- the polymers and/or the copolymers based on polyester, acrylonitrile or polyvinylidene fluoride can be cited amongst the possible materials: the polymers and/or the copolymers based on polyester, acrylonitrile or polyvinylidene fluoride.
- the mean size of the pores of the filter medium is chosen according to the biological fluid to be treated.
- the mean size of the pores can be of the order of or greater than 7 ⁇ m.
- the mean size of the pores can be smaller, for example of the order of 4 ⁇ m, on account of the absence of cellular constituents in the plasma.
- the contact area between the biological fluid and the filter medium must be sufficient to remove substantially all the virucidal substance while leaving the composition of the biological fluid substantially unchanged.
- spunbond and “meltblown” mean two of the conventional methods of forming a layer of non-woven material directly from the polymer, namely respectively either by forming continuous monofilaments or by blowing the polymer in the molten state into irregular filaments.
- the two outer layers of “spunbond” non-woven material are identical and serve respectively as a pre- and post-filter. Furthermore, they have the function of improving the weldability of the filter medium 5 onto the casing 2 of the filtration unit 1 .
Abstract
A filtering unit for removing a virucidal substance from a biological fluid including an outer casing having at least one input aperture and at least one output aperture. The outer casing including a filter medium, which separates the filtration unit into an input compartment and an output compartment. The filter medium includes at least one hydrophilic material able to absorb or adsorb the virucidal substance. The at least one hydrophilic material includes either porous non-woven material or a porous membrane.
Description
- The invention relates to a filtration unit intended to remove a virucidal substance present in a biological fluid.
- It typically applies to the case where the virucidal substance has previously been added to a biological fluid, in particular blood plasma, intended to be transfused into a patient. The aim of this addition is to subject the biological fluid to a viral inactivation treatment prior to its transfusion into the patient, so as to inactivate any viruses infecting the biological fluid.
- A conventional technique for viral inactivation of plasma uses a colouring substance as a virucidal substance, for example methylene blue or one of its derivatives.
- The principle of this technique is based on photochemical reactions between the colouring substance and the viral DNA or RNA which may be present in the biological fluid.
- Exposure of the colouring substance to light brings about a photochemical reaction which transmits energy to the DNA and RNA molecules so that the virus is inactivated.
- During these photochemical reactions, the colouring substance is not removed so that it remains in the biological fluid after exposure to light.
- After the use of this viral inactivation technique, a very small amount of the colouring substance may be left in the biological fluid and thus be transfused into the patient at the same time as the biological fluid.
- However, recent studies seem to show the possible toxicity of certain colouring substances used, and in particular methylene blue, when they are injected into the patient.
- So much so that many countries are demanding the systematic removal of colouring substances prior to injection of the biological fluid into the patient.
- The invention therefore aims to propose a filtration unit which makes it possible to remove substantially all the virucidal substance present in the biological fluid while leaving the composition of the biological fluid substantially unchanged during the filtration.
- To that end, the object of the invention is a filtration unit intended to remove a virucidal substance present in a biological fluid, comprising an outer casing provided with at least one input aperture and at least one output aperture, the casing containing a filter medium which delimits two compartments, respectively input and output, of the filtration unit, in which the filter medium is produced from at least one hydrophilic material in the form of a porous non-woven material and/or a porous membrane capable of absorbing and/or adsorbing the virucidal substance.
- According to one embodiment, the mean porosity of the filter medium is defined so that the contact area between the biological fluid and the filter medium is sufficient to remove substantially all the virucidal substance while leaving the composition of the biological fluid substantially unchanged during its passage through the filter medium, namely being between 1 μm and 15 μm.
- In a variant, the mean diameter of the fibres of the porous non-woven material is between 0.5 μm and 5 μm.
- The input compartment and/or the output compartment communicate with the outside of the filtration unit by means of an input, respectively output, tube.
- The hydrophilic material of the filter medium is chosen in particular from amongst the naturally hydrophilic materials or the materials, in particular based on plastic material, made hydrophilic, for example from amongst the polymers and/or the copolymers based on polyester, acrylonitrile or polyvinylidene fluoride.
- According to one embodiment, the filter medium comprises a number of layers of hydrophilic material, identical or different in nature to one another, with a contact area identical or different to one another.
- The filter medium has for example a thickness between 1 and 10 millimetres.
- According to one embodiment, the outer casing of the filtration unit is rigid.
- According to another embodiment, the outer casing of the filtration unit is flexible.
-
FIG. 3 depicts, in top view and transverse section, the embodiment ofFIG. 1 , showing in particular the assembly of the frame containing the filter medium in the outer casing. -
FIG. 4 depicts, in front view and partial longitudinal section, the filtration unit ofFIG. 3 in which the spacing rods appear. - A
filtration unit 1 intended to remove a virucidal substance present in a biological fluid comprises typically anouter casing 2 provided with at least one input aperture 3 and at least oneoutput aperture 4, the casing containing afilter medium 5 which delimits two compartments, respectively input 6 andoutput 7, of thefiltration unit 1. - In the description, the words “input” and “output” are defined with respect to the direction of movement of the biological fluid in the filtration unit 1 (see the arrows shown in
FIG. 1 ). - According to one particular embodiment, the biological fluid is blood or a blood compound, in particular blood plasma, and the virucidal substance is methylene blue or one of its derivatives.
- Prior to its passage into the
filtration unit 1, the biological fluid has undergone a viral inactivation treatment by means of the virucidal substance which was added to the biological fluid. - This treatment, generally used at the blood transfusion centre, will not be described further here.
- The
filtration unit 1 is intended to be integrated, in particular by means of tubes, respectively input 8 and output 9, into a system comprising for example bags for medical use, tubes, clamps or other filters (for example to remove leukocytes from the biological fluid). - In such a system, the
filtration unit 1 is disposed on the flow path of the biological fluid so that the biological fluid with the virucidal substance added enters thefiltration unit 1 by the input aperture 3 and the biological fluid free from the virucidal substance is delivered by means of theoutput aperture 4. - One particular example of such a system is a transfusion line of a bag containing a biological fluid to be transfused into a patient. In such a line, the
filtration unit 1 is connected by its input 3 to the bag containing the biological fluid with the virucidal substance added and by itsoutput 4 to means of transfusion of the biological fluid free from virucidal substance. - These various systems are not described further inasmuch as they comprise the
filtration unit 1 according to the structure described here. - A description is now given of a first embodiment of the
filtration unit 1 comprising a flexibleouter casing 2 formed by the assembly of two sheets of flexibleplastic material FIG. 1 ). - This outer casing contains a filter medium designated generally by the
reference 5, the structure of which will be described in more detail below. - The
filter medium 5 is held in a flexible andimpervious support frame 12 and delimits two compartments, respectively input 6 andoutput 7, of thefiltration unit 1. - The
input compartment 6 communicates with the outside of thefiltration unit 1 by means of aninput tube 8 which is used to fill it with the biological fluid with the virucidal substance added. - The
output compartment 7 communicates with the outside of thefiltration unit 1 by means of an output tube 9 which delivers the biological fluid free from virucidal substance. - The structure of the
filtration unit 1 thus allows the biological fluid with the virucidal substance added to be received in theinput compartment 6 via the input aperture 3, to pass through thefilter medium 5 so that the virucidal substance is absorbed and/or adsorbed thereby, and then the biological fluid free from virucidal substance is received in theoutput compartment 7 in order to be delivered via theoutput aperture 4. - According to one embodiment, the
input tubes 8 and/or output tubes 9 are flexible, and can be cut and welded. - Where a collecting bag is associated with the output tube 9, this embodiment makes it possible, after separation of the
filtration unit 1 by cutting and welding of the output tube 9, to obtain a bag full of biological fluid free from virucidal substance. Such a bag can then be used conventionally, for example for transfusion into a patient. - A first level of sealing of the
filtration unit 1 is provided between thefilter medium 5 and theflexible frame 12 where no tube passes. - A second level of sealing is provided at the periphery of the
filtration unit 1 where the twoouter sheets flexible frame 12 and the passage of theinput tube 8 and output tube 9 come together. - This second level of sealing can be provided by the known techniques for connecting plastic materials, for example by high-frequency welding.
- The implementation of the assembly of the
filtration unit 1 is now described with reference toFIGS. 2 to 4 . - The
flexible frame 12 is formed by an assembly of twosheets filter medium 5 is placed. - These two
sheets - The two
sheets filter medium 5, for example by aweld seam 17, made through thefilter medium 5, providing both the fixing of thefilter medium 5 and also the sealing of theunit 1. - The welding of the
sheets filter medium 5 causes acompression 18, forming an impervious seam around thefilter medium 5. - The
periphery 19 of theflexible frame 12 is also welded with theouter sheets outer casing 2 of thefiltration unit 1, these being welded to one another over their entire circumference and in the region of their periphery, thus providing the sealing of theunit 1. - In order to avoid the
filter medium 5 sticking against theouter casing 2, and thus interfering with the flow of the biological fluid into theoutput compartment 7, twospacing rods output compartment 7, between thefilter medium 5 and theouter casing 2. - These two
rods output compartment 7 clear of thefilter medium 5 and thus avoid thefilter medium 5 being flattened against the inner wall of theouter sheet 2. - The
rods outer casing 2, for example in the region of theperipheral weld 19 of thefiltration unit 1. - It is self-evident that the number of spacing rods can vary, depending for example on the dimensions of the
filtration unit 1. - For example, provision of a single spacing rod folded so as to form a loop inside the
output compartment 7 can be envisaged. - Preferably, flexible rods are used, in order not to interfere with the possibilities of folding the
filtration unit 1. - In a second embodiment (not depicted), the
filtration unit 1 comprises a rigidouter casing 2, for example made of a rigid plastic material such as polycarbonate. - There will now be described in more detail the structure and implementation of the
filter medium 5 capable of removing substantially all the virucidal substance while leaving the composition of the biological fluid substantially unchanged during the filtration. - In a first embodiment, the
filter medium 5 is produced from at least one hydrophilic material in the form of a porous non-woven material. - In a second embodiment, the
filter medium 5 is produced from at least one hydrophilic material in the form of a porous membrane. - In a third embodiment, the
filter medium 5 is produced from a hydrophilic material in the form of at least one porous membrane which is inserted between a number of layers of hydrophilic material in the form of a non-woven material. - In these three embodiments, the hydrophilic material is capable of absorbing and/or adsorbing the virucidal substance, in particular by affinity between the virucidal substance and the hydrophilic material.
- Various materials can be used for producing the filter medium depending on the nature of the fluid to be filtered and that of the biological fluid.
- The choice of materials usable in the filtration unit according to the invention is however limited by the fact that they must not prevent, in particular by affinity, the passage of the cellular or non-cellular constituents of the biological fluid.
- In other words, the material forming the filter medium must be capable of absorbing and/or adsorbing the virucidal substance but not the constituents of the biological fluid.
- In the case of treatment of a blood plasma containing methylene blue, the following can be cited amongst the possible materials: the polymers and/or the copolymers based on polyester, acrylonitrile or polyvinylidene fluoride.
- These polymeric products are generally not naturally hydrophilic and must be treated by physical and/or chemical methods, in order to give them said hydrophilic properties.
- These treatments consist for example in grafting hydrophilic substituents, for example hydroxyl or carboxylic type groups, onto the polymer, according to known methods.
- Such polymers made hydrophilic by physical and/or chemical treatment are available on the market.
- The hydrophilic nature of the material forming the
filter medium 5 allows a good wettability of the filter medium during passage of the biological fluid, which allows in particular a better flow of the biological fluid through thefiltration unit 1 but also an improvement in the filtration efficiency. - The porosity characteristics of the filter medium allow the passage of the biological fluid through the filtration unit while leaving the composition of the biological fluid substantially unchanged.
- To that end, the mean size of the pores of the filter medium is chosen according to the biological fluid to be treated. For example, for the
filtration unit 1 to allow the constituents of whole blood to pass, the mean size of the pores can be of the order of or greater than 7 μm. In the case of blood plasma, the mean size of the pores can be smaller, for example of the order of 4 μm, on account of the absence of cellular constituents in the plasma. - During passage of the biological fluid with the virucidal substance added through the
filter medium 5, the contact area between the biological fluid and the filter medium must be sufficient to remove substantially all the virucidal substance while leaving the composition of the biological fluid substantially unchanged. - In the first embodiment, this characteristic is advantageously obtained by means of the use of a non-woven material which has, through its structure, a large contact area for a small volume.
- Contact area between the biological fluid and the filter medium means the area over which the absorption and/or adsorption of the virucidal substance by the porous material can take place. It is self-evident that this area is a function in particular of the area of the filter medium, its porosity, its thickness and the diameter of the fibres of the non-woven material.
- Thus, by changing the diameter of the fibres, the porosity of the non-woven material and the thickness of the
filter medium 5 it composes, access can be obtained to a wide range of contact areas which makes it possible to remove substantially all the virucidal substance while leaving the composition of the biological fluid substantially unchanged. - By way of example, there can be cited a
filter medium 5 formed from a non-woven material made of polyester having a thickness of the order of 5 mm, a mean porosity of the order of 8 μm and a mean fibre diameter of the order of 2 μm, allowing the removal of a concentration of 1 μM of methylene blue in 250 ml of blood plasma. - It should be noted however that these values can vary to a great extent, in particular according to the time of contact between the filter medium and the biological fluid, that is to say the filtration speed.
- In the second embodiment, a porous membrane is used as the
filter medium 5 to absorb and/or adsorb the virucidal substance present in the biological fluid. - In one particular example, such a membrane is made of polyvinylidene fluoride and with a pore size calibrated to a value between 1 and 15 μm.
- In the third embodiment, the
filter medium 5 can combine the two materials used in the preceding embodiments, namely comprise a number of layers of hydrophilic material in the form of a porous non-woven material and one or more porous membranes. The material and/or the structure of the material forming these layers can then be identical or different to one another. - The layers are then disposed, for example contiguously, next to one another in the filtration unit so that the biological fluid passes through them successively during the filtration.
- In one particular example, there can be cited a
filter medium 5 formed from a superposition of layers formed respectively of a “spunbond” type polyester non-woven material, a “meltblown” type polyester non-woven material, one or more polyvinylidene fluoride membranes, a “meltblown” type polyester non-woven material and a “spunbond” type polyester non-woven material. - The words “spunbond” and “meltblown” mean two of the conventional methods of forming a layer of non-woven material directly from the polymer, namely respectively either by forming continuous monofilaments or by blowing the polymer in the molten state into irregular filaments.
- As these techniques are conventional, they will not be detailed further here.
- In this embodiment, the two outer layers of “spunbond” non-woven material are identical and serve respectively as a pre- and post-filter. Furthermore, they have the function of improving the weldability of the
filter medium 5 onto thecasing 2 of thefiltration unit 1. - The two layers of “meltblown” non-woven material and the membrane or membranes placed between them form more particularly the
filter medium 5 capable of absorbing and/or adsorbing the virucidal substance. - Furthermore, the two layers of “meltblown” non-woven material are identical and have the function of protecting the membrane or membranes.
Claims (25)
1-20. (canceled)
21. A method for eliminating a virucidal substance from a biological fluid comprising:
passing the biological fluid through a filter medium produced from a treate, hydrophilic polymer or copolymer capable of absorbing or adsorbing the virucidal substance and having a porosity that allows passage of the biological fluid through the filter medium; wherein the polymer or copolymer comprises polyester, acrylonitrile, or polyvinylidene fluoride.
22. The method according to claim 21 , wherein the biological fluid comprises blood, serum or plasma.
23. The method according to claim 21 , wherein the virucidal substance comprises methylene blue.
24. The method according to claim 22 , wherein the methylene blue has a concentration of 1 μM.
25. The method according to claim 21 , wherein the treated, hydrophilic polymer or copolymer comprises treated, hydrophilic polyester.
26. The method according to claim 21 , wherein the treated, hydrophilic polymer or copolymer comprises treated, hydrophilic acrylonitrile.
27. The method according to claim 21 , wherein the treated, hydrophilic polymer or copolymer comprises treated, hydrophilic polyvinylidene fluoride.
28. A method of forming a filter medium comprising:
treating a polymer or copolymer to render it hydrophilic and capable of absorbing or adsorbing a virucidal substance, said polymer or copolymer comprising polyester, acrylonitrile or polyvinylidene fluoride; and
forming a filter medium containing the polymer or copolymer, wherein the filter medium has a mean porosity of between 1 μm and 15 μm.
29. The method according to claim 28 , wherein treating comprises grafting a hydrophilic substituent to the polymer or copolymer to render it hydrophilic and capable of absorbing or adsorbing a virucidal substance.
30. The method according to claim 29 , wherein the hydrophilic substituent comprises a hydroxyl or a carboxylic group.
31. (canceled)
32. A method of forming a filtration unit comprising:
treating a polymer or copolymer to render it hydrophilic and capable of absorbing or adsorbing a virucidal substance, said polymer or copolymer comprising polyester, acrylonitrile or polyvinylidene fluoride;
forming a filter medium containing the polymer or coplymer, wherein the filter medium has a mean porosity of between 1 μm and 15 μm;
placing the filter medium in a casing having an inlet aperture and an outlet aperture to form a filtration unit.
33. The method according to claim 32 wherein treating comprises grafting a hydrophilic substituent to the polymer or copolymer to render it hydrophilic and capable of absorbing or adsorbing a virucidal substance.
34. The method according to claim 33 , wherein the hydrophilic substituent comprises a hydroxyl or a carboxylic group.
35. The method according to claim 32 , wherein the polymer or copolymer comprises polyester.
36. The method according to claim 32 , wherein the polymer or copolymer comprises acrylonitrile.
37. The method according to claim 32 , wherein the polymer or coplymer comprises polyvinylidene fluoride.
38. The method according to claim 32 , wherein the filter medium has a thickness between 1 and 10 millimeters.
39. The method according to claim 32 , wherein the filter medium comprises non-woven fibers having a mean diameter of between 0.5 μm and 5 μm.
40. The method according to claim 32 , wherein the casing comprises an inlet aperture and an outlet aperture.
41. The method according to claim 21 , wherein the filter medium has a mean porosity of between 1 μm and 15 μm.
42. The method according to claim 21 , wherein the treated, hydrophilic polymer or copolymer is in the form or a membrane.
43. The method according to claim 21 , wherein the treated, hydrophilic polymer or copolymer is in the form of non-woven fibers.
44. The method according to claim 21 , wherein the treated, hydrophilic polymer or copolymer is in the form of a porous non-woven material and one or more porous membranes.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/053,929 US20090071905A1 (en) | 1999-10-20 | 2008-03-24 | Methods of Making and Using Filtering Unit for a Virucide Substance |
US13/089,636 US8986237B2 (en) | 1999-10-20 | 2011-04-19 | Methods of making and using filtering unit for a virucide substance |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR99/13089 | 1999-10-20 | ||
FR9913089A FR2799986B1 (en) | 1999-10-20 | 1999-10-20 | FILTER UNIT OF A VIRUCID SUBSTANCE |
PCT/FR2000/002900 WO2001028597A1 (en) | 1999-10-20 | 2000-10-18 | Filtering unit for a virucide substance |
US11114302A | 2002-04-19 | 2002-04-19 | |
US12/053,929 US20090071905A1 (en) | 1999-10-20 | 2008-03-24 | Methods of Making and Using Filtering Unit for a Virucide Substance |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/002900 Continuation WO2001028597A1 (en) | 1999-10-20 | 2000-10-18 | Filtering unit for a virucide substance |
US10111143 Continuation | 2000-10-18 | ||
US11114302A Continuation | 1999-10-20 | 2002-04-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/089,636 Continuation US8986237B2 (en) | 1999-10-20 | 2011-04-19 | Methods of making and using filtering unit for a virucide substance |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090071905A1 true US20090071905A1 (en) | 2009-03-19 |
Family
ID=9551138
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/053,929 Abandoned US20090071905A1 (en) | 1999-10-20 | 2008-03-24 | Methods of Making and Using Filtering Unit for a Virucide Substance |
US13/089,636 Expired - Fee Related US8986237B2 (en) | 1999-10-20 | 2011-04-19 | Methods of making and using filtering unit for a virucide substance |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/089,636 Expired - Fee Related US8986237B2 (en) | 1999-10-20 | 2011-04-19 | Methods of making and using filtering unit for a virucide substance |
Country Status (10)
Country | Link |
---|---|
US (2) | US20090071905A1 (en) |
EP (1) | EP1093823B1 (en) |
JP (1) | JP2003512093A (en) |
AT (1) | ATE367170T1 (en) |
AU (1) | AU7930500A (en) |
CA (1) | CA2387848C (en) |
DE (1) | DE60035560T2 (en) |
ES (1) | ES2290004T3 (en) |
FR (1) | FR2799986B1 (en) |
WO (1) | WO2001028597A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170014567A1 (en) * | 2014-03-10 | 2017-01-19 | Asahi Kasei Medical Co., Ltd. | Blood treatment filter |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10188782B2 (en) | 2013-10-02 | 2019-01-29 | Asahi Kasei Medical Co., Ltd. | Blood processing filter and blood processing method |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2797403B1 (en) * | 1999-08-09 | 2002-03-15 | Maco Pharma Sa | TRANSFUSION LINE WITH MEANS FOR FILTERING A COLORED SUBSTANCE |
ITTO20020736A1 (en) * | 2002-08-21 | 2004-02-22 | Fresenius Hemocare Italia Srl | LEukocyte filter and its use for the depletion of leukocyte blood products. |
EP1579838A4 (en) * | 2002-12-12 | 2007-11-28 | Asahi Chemical Ind | Virus-removing bag and virus-removing method using the same |
US7534348B2 (en) * | 2003-09-12 | 2009-05-19 | Fenwal, Inc. | Flow-through removal device and system using such device |
EP1685852A1 (en) * | 2005-02-01 | 2006-08-02 | Fondation pour la Recherche Diagnostique | Set of disposable bags for viral inactivation of biological fluids |
FR2897783B1 (en) * | 2006-02-24 | 2008-05-30 | Millipore Corp | DEVICE FOR MICROBIOLOGICAL CONTROL, CONTROL AND INCUBATION ASSEMBLIES COMPRISING THE SAME, AND METHOD FOR CARRYING OUT THE SAME |
CN102302877B (en) * | 2011-06-01 | 2013-06-12 | 李红 | Biological protection filter medium and application thereof |
US10213534B2 (en) * | 2013-10-03 | 2019-02-26 | Asahi Kasei Medical Co., Ltd. | Blood processing filter and blood processing filter manufacturing method |
CN113509919B (en) * | 2021-05-01 | 2023-01-10 | 南开大学 | Adsorbent for removing endotoxin and inflammatory factor in blood of sepsis patient and preparation method thereof |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4159954A (en) * | 1978-02-24 | 1979-07-03 | Gangemi Ronald J | Isolator filter |
US4276170A (en) * | 1978-08-16 | 1981-06-30 | Critikon, Inc. | Vented flexible filtration device for use in administering parenteral liquids |
US4701267A (en) * | 1984-03-15 | 1987-10-20 | Asahi Medical Co., Ltd. | Method for removing leukocytes |
US4925572A (en) * | 1987-10-20 | 1990-05-15 | Pall Corporation | Device and method for depletion of the leukocyte content of blood and blood components |
US4985153A (en) * | 1988-06-23 | 1991-01-15 | Asahi Medical Co., Ltd. | Method for separating blood into blood components, and blood components separator unit |
US5234593A (en) * | 1989-09-18 | 1993-08-10 | Terumo Kabushiki Kaisha | Filter for purification of platelets |
US5478470A (en) * | 1991-08-22 | 1995-12-26 | Asahi Medical Co., Ltd. | Filter material for selectively removing leukocytes |
US5639376A (en) * | 1994-01-10 | 1997-06-17 | Hemasure, Inc. | Process for simultaneously removing leukocytes and methylene blue from plasma |
US5858641A (en) * | 1996-09-17 | 1999-01-12 | Shanbrom Technologies, Llc | Disinfectant dye removal from blood and blood fractions using a porous poly(vinyl alcohol-acetal) copolymer |
US6197207B1 (en) * | 1997-05-21 | 2001-03-06 | Baxter International Inc. | Method of reducing the possibility of transmission of spongiform encephalopathy diseases by blood products |
US6328167B1 (en) * | 1998-12-28 | 2001-12-11 | Fuji Photo Film Co., Ltd. | Blood filter cartridge |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319662B1 (en) * | 1993-12-17 | 2001-11-20 | Baxter International Inc. | Method and apparatus for removing viral contaminants from a body fluid |
US6190855B1 (en) * | 1996-10-28 | 2001-02-20 | Baxter International Inc. | Systems and methods for removing viral agents from blood |
AU1056397A (en) * | 1996-11-20 | 1998-06-10 | Edward Shanbrom | Trace capture in biological fluids |
-
1999
- 1999-10-20 FR FR9913089A patent/FR2799986B1/en not_active Expired - Lifetime
-
2000
- 2000-10-18 ES ES00402885T patent/ES2290004T3/en not_active Expired - Lifetime
- 2000-10-18 DE DE60035560T patent/DE60035560T2/en not_active Expired - Lifetime
- 2000-10-18 EP EP00402885A patent/EP1093823B1/en not_active Expired - Lifetime
- 2000-10-18 JP JP2001531425A patent/JP2003512093A/en active Pending
- 2000-10-18 AT AT00402885T patent/ATE367170T1/en not_active IP Right Cessation
- 2000-10-18 CA CA002387848A patent/CA2387848C/en not_active Expired - Lifetime
- 2000-10-18 WO PCT/FR2000/002900 patent/WO2001028597A1/en active Application Filing
- 2000-10-18 AU AU79305/00A patent/AU7930500A/en not_active Abandoned
-
2008
- 2008-03-24 US US12/053,929 patent/US20090071905A1/en not_active Abandoned
-
2011
- 2011-04-19 US US13/089,636 patent/US8986237B2/en not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4159954A (en) * | 1978-02-24 | 1979-07-03 | Gangemi Ronald J | Isolator filter |
US4276170A (en) * | 1978-08-16 | 1981-06-30 | Critikon, Inc. | Vented flexible filtration device for use in administering parenteral liquids |
US4701267B1 (en) * | 1984-03-15 | 1996-03-12 | Asahi Medical Co | Method for removing leukocytes |
US4701267A (en) * | 1984-03-15 | 1987-10-20 | Asahi Medical Co., Ltd. | Method for removing leukocytes |
US4925572A (en) * | 1987-10-20 | 1990-05-15 | Pall Corporation | Device and method for depletion of the leukocyte content of blood and blood components |
US4985153A (en) * | 1988-06-23 | 1991-01-15 | Asahi Medical Co., Ltd. | Method for separating blood into blood components, and blood components separator unit |
US5234593A (en) * | 1989-09-18 | 1993-08-10 | Terumo Kabushiki Kaisha | Filter for purification of platelets |
US5478470A (en) * | 1991-08-22 | 1995-12-26 | Asahi Medical Co., Ltd. | Filter material for selectively removing leukocytes |
US5665233A (en) * | 1991-08-22 | 1997-09-09 | Asahi Medical Co., Ltd. | Filter apparatus for selectively removing leukocytes |
US5639376A (en) * | 1994-01-10 | 1997-06-17 | Hemasure, Inc. | Process for simultaneously removing leukocytes and methylene blue from plasma |
US5858641A (en) * | 1996-09-17 | 1999-01-12 | Shanbrom Technologies, Llc | Disinfectant dye removal from blood and blood fractions using a porous poly(vinyl alcohol-acetal) copolymer |
US6197207B1 (en) * | 1997-05-21 | 2001-03-06 | Baxter International Inc. | Method of reducing the possibility of transmission of spongiform encephalopathy diseases by blood products |
US6328167B1 (en) * | 1998-12-28 | 2001-12-11 | Fuji Photo Film Co., Ltd. | Blood filter cartridge |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10188782B2 (en) | 2013-10-02 | 2019-01-29 | Asahi Kasei Medical Co., Ltd. | Blood processing filter and blood processing method |
US20170014567A1 (en) * | 2014-03-10 | 2017-01-19 | Asahi Kasei Medical Co., Ltd. | Blood treatment filter |
CN108635629A (en) * | 2014-03-10 | 2018-10-12 | 旭化成医疗株式会社 | blood processing filter |
US10842927B2 (en) * | 2014-03-10 | 2020-11-24 | Asahi Kasei Medical Co., Ltd. | Blood treatment filter |
US11504460B2 (en) * | 2014-03-10 | 2022-11-22 | Asahi Kasei Medical Co., Ltd. | Blood treatment filter |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10183475B2 (en) | 2014-03-24 | 2019-01-22 | Fenwal, Inc. | Flexible biological fluid filters |
US10343093B2 (en) | 2014-03-24 | 2019-07-09 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
Also Published As
Publication number | Publication date |
---|---|
ES2290004T3 (en) | 2008-02-16 |
EP1093823B1 (en) | 2007-07-18 |
US8986237B2 (en) | 2015-03-24 |
FR2799986A1 (en) | 2001-04-27 |
AU7930500A (en) | 2001-04-30 |
DE60035560T2 (en) | 2008-04-17 |
CA2387848A1 (en) | 2001-04-26 |
EP1093823A1 (en) | 2001-04-25 |
FR2799986B1 (en) | 2001-11-23 |
US20110192798A1 (en) | 2011-08-11 |
CA2387848C (en) | 2008-10-07 |
JP2003512093A (en) | 2003-04-02 |
DE60035560D1 (en) | 2007-08-30 |
ATE367170T1 (en) | 2007-08-15 |
WO2001028597A1 (en) | 2001-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8986237B2 (en) | Methods of making and using filtering unit for a virucide substance | |
US8123940B2 (en) | Filtration unit for the selective elimination of a target substance | |
US20070175816A1 (en) | Filtering Unit Having A Calendered Layer For Removing Leukocytes | |
US5639376A (en) | Process for simultaneously removing leukocytes and methylene blue from plasma | |
US6159375A (en) | Method for removing leukocytes and methylene blue from plasma | |
KR100743483B1 (en) | Virus-removing bag and virus-removing method using the same | |
US7591954B2 (en) | Method for removing leukocytes, leukocyte-removing filter and utilization thereof | |
US5258127A (en) | Leucocyte depleting filter device and method of use | |
US5540841A (en) | Cardioplegia filter and method for processing cardioplegia fluid | |
WO1994017894A1 (en) | Leukocyte removal method and filter unit for same | |
CN107735116B (en) | Filter member for blood treatment filter and blood treatment filter | |
CN109562210B (en) | Filter element for blood treatment filter, and method for removing leukocytes | |
AU722640B2 (en) | Method for purifying blood plasma and apparatus suitable therefor | |
CN117062660A (en) | Filter medium | |
JP5036026B2 (en) | Blood component separation device and method of use thereof | |
EP1002566B1 (en) | Filter for adsorbing heparin and/or endotoxins in plasma and/or blood | |
US20130292320A1 (en) | Filtering unit having a calendered layer for removing leukocytes | |
US20230040306A1 (en) | System for selective removal of a target substance from a biological fluid | |
JP2008173163A (en) | Blood purifier and method for producing the same | |
RU2802136C1 (en) | System and method for treatment of blood and its components by selective removal of target substance | |
JP3356844B2 (en) | Blood purification system | |
JPH08173528A (en) | Blood processing system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MACOPHARMA, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOUDALIEZ, FRANCIS;VERPOORT, THIERRY;REEL/FRAME:022095/0201 Effective date: 20020409 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |